Table 2.
Univariate and multivariate analysis for overall survival (OS) in patients with advanced gastric cancer (AGC), who received neoadjuvant chemotherapy (NAC).
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Variables | p -value | HR | 95%CI | p -value |
| Sex | 0.408 | |||
| Male/female | ||||
| Age (yr) | 0.413 | |||
| <60/≥60 | ||||
| Chemotherapy regimen | 0.486 | |||
| SOX/XELOX/FLOT/others | ||||
| Differentiation | 0.029 | 0.485 | 0.246–1.537 | 0.299 |
| High & medium/Low,• signet-ring cell carcinoma,• mucinous adenocarcinoma | ||||
| Tumor size (cm) | 0.714 | |||
| <5/≥5 | ||||
| Tumor location | 0.004 | 1.127 | 0.981–9.713 | 0.054 |
| Upper/meddle/lower | ||||
| pT stage | 0.454 | |||
| 1/2/3/4 | ||||
| Lymphatic metastasis | 0.698 | |||
| Yes/no | ||||
| Venous invasion | 0.039 | 0.473 | 0.289–1.342 | 0.227 |
| Yes/no | ||||
| Recurrence | 0.168 | |||
| Yes/no | ||||
| Metastasis | <0.001 | 1.920 | 0.062–0.345 | <0.001 |
| Yes/no | ||||
| Pre-chemotherapy NLR | 0.403 | |||
| <2.28/≥2.28 | ||||
| Post-chemotherapy NLR | 0.002 | 0.516 | 0.202–1.763 | 0.350 |
| <1.75/≥1.75 | ||||
| Change of NLR | <0.001 | 1.945 | 2.180–22.438 | 0.001 |
| Increase/decrease | ||||
NLR, neutrophil-to-lymphocyte ratio; pT, pathological T stage; DFS, disease-free survival; CI, confidence interval; HR, hazard ratio.